Massachusetts fights off challengers to its life science dominance
Hannah Green, Boston Business Journal
Over the last several decades, Massachusetts has built itself into the No. 1 biotech hub in the world.
The numbers demonstrate the state’s dominance in life sciences. Nearly $7.9 billion in venture capital flowed to Bay State biotechs in 2024. Eighteen of the top 20 pharma companies have a presence in Massachusetts. And the state routinely brings in more NIH funding per capita than any other state.
But in recent years, threats have been building to Massachusetts’ lead as other states and countries invest in the sector. Just this year, the NIH funding cuts, FDA layoffs and proposed pharmaceutical tariffs under the Trump administration have introduced new chaos to Massachusetts’ life sciences industry.
Yet while there are growing threats to the life sciences industry here, political leaders and executives aren’t throwing in the towel. Here’s how the fight to protect Massachusetts’ life sciences dominance is being waged.
In addition to longstanding rivals like California, other states including North Carolina and Texas have recently gained attention as life sciences hubs.
North Carolina has been investing in biotech for decades, creating the North Carolina Biotechnology Center (NCBiotech) in 1984. NCBiotech’s president and CEO Doug Edgeton called it the nation’s first state-sponsored initiative in biotechnology development.
For the full article, please go to: